eBV is Fast. That Doesn't Mean Your Benefit Verification is.

The pitch for electronic benefit verification is compelling and, in isolation, accurate. You submit a handful of data points and receive coverage information in seconds rather than hours or even days. For a system historically dominated by phone trees, fax machines, and hold music, that kind of efficiency sounds like a meaningful leap forward. And for straightforward cases, it is.

The problem is that specialty and rare disease access programs are not built on straightforward cases. And when the conversation shifts from what eBV can do in ideal conditions to what it actually produces across the full range of patients a hub program manages, the picture changes considerably.

What the standard actually captures

Electronic benefit verification works by querying payer systems through established data exchange protocols, primarily EDI 270/271 transactions. These standards were designed to confirm whether coverage exists and return basic financial data: active coverage status, plan type, product line, deductibles, and out-of-pocket accumulators. For those purposes, they perform exactly as designed.

The issue is what falls outside of that scope. These data standards were built to exchange coverage data. They accurately return active coverage status, product line, and basic financials, but they were never intended to express therapy-specific rules, prior authorization criteria, step therapy sequences, quantity limits, or specialty pharmacy requirements (Source: Neonhealth). For a patient on a specialty or rare disease therapy, those are precisely the details that determine whether access happens and how fast.

Research has found that around 60% of electronic verification results are actually accurate, and more than 70% of prior authorization submissions are rejected with little to no reporting on the patient's status (Source: Eversana). A result that returns quickly but leaves half the access picture incomplete is not, in any meaningful sense, a completed verification.

The data is chronically incomplete for specialty programs

The standard gap between what eBV returns and what specialty access requires is not a technology failure. The technology is working as designed. The gap is structural: the complexities associated with specialty medications result in an insurance landscape that is difficult to navigate, with coverage rules and requirements often changing without notice. Logic-based solutions represent a static snapshot of the coverage landscape at a specific point in time and can quickly become outdated and inaccurate (Source: PM360).

Several categories of information are almost never captured by a standard eBV query. Step therapy requirements, which mandate that a patient try and fail certain therapies before a brand-name specialty drug is approved, vary by payer, product, and plan year. Carve-out benefits, where certain services like pharmacy benefits are managed by separate vendors, require manual outreach that falls entirely outside what eBV returns (Source: careviso). High-cost specialty medications frequently trigger additional authorization layers. That, and the fact that specialty medications are split into two administrative silos, with the pharmacy benefit on one side and the medical benefit on the other operating with completely different rules for prior authorizations, creates complexity that standard eBV tools struggle to navigate. DrFirst.com, Inc.

The result is a verification that confirms a patient has insurance but cannot tell you what that insurance means for the therapy they need.

What happens when the data is incomplete

When a standard eBV query returns a partial result for a specialty patient, someone still must resolve the missing information. That resolution is not fast. Incomplete or missing documentation forces teams to redo the entire verification, and each component of the benefit determination introduces latency, fragmentation, and human interpretation (Source: Neonhealth). For team members who aren’t doing benefit verifications regularly, these discrepancies can be wide.

The workflow that follows an incomplete eBV result typically involves direct payer outreach by phone, cross-referencing multiple portal systems for medical versus pharmacy benefit details, checking for carve-out vendor routing, verifying step therapy compliance documentation, and confirming specialty pharmacy network requirements. Benefit verification for specialty prescriptions is not one task; it is dozens of microtasks, stitched together manually, repeated thousands of times across the healthcare system.

Manual benefit verification volume increased 38% year-over-year in 2024, and partially electronic benefit verification is declining because specialty workflows cannot be partially automated. Automation that hands off mid-process to a human who must then rebuild the full picture does not compress the timeline in any meaningful way for the cases that need it most. It often just front-loads the easy part and defers the hard part.

What pharma manufacturers are trading for speed

When a hub vendor leads with eBV speed as a primary differentiator, the implicit trade-off deserves scrutiny. A fast result on an incomplete data set does not accelerate patient access. In many cases, it creates a false signal of progress that delays the focused intervention the case always needed.

Pharma manufacturers should be skeptical of any vendor that presents eBV turnaround time as an independent measure of access performance. The questions that matter more are: what percentage of benefit verifications are returned complete on the first query? What process handles the cases where the electronic result is partial or unavailable? How does the system distinguish between a verification that is finished and one that is simply closed?

The system is catching up, but it isn't there yet

The technology infrastructure that would make true real-time, complete electronic benefit verification possible for specialty drugs is actively developing. Regulatory pressure around prior authorization transparency and interoperability is creating incentives for payers to modernize legacy systems.

The critical success factors for a next-generation eBV solution focus on two key components: confidence in the accuracy of the benefit information being provided and the speed-to-treatment for the patient. The best approach is hybrid, combining AI and machine-learning technology with expert human expertise and intervention to process complex verifications (Source: PharmExec)

While progress is being made, the gap between where the field is heading and where payer data infrastructure operates today is real and consequential for every hub program running now. Specialty medications account for a disproportionate share of verification complexity, and the payer systems that hub programs query every day do not yet return the full picture consistently. That gap does not disappear because an eBV transaction is completed in four seconds.

What a reliable program actually requires

Effective benefit verification for specialty and rare disease programs requires a system designed around both scenarios: cases where the electronic query returns complete data and can move quickly, and cases where it does not and requires structured human intervention. Those two categories need to be handled deliberately, not treated as variations of the same workflow.

For straightforward verifications, automation should move the case forward without delay. For verifications where the eBV result is partial, a defined escalation path to a trained specialist needs to activate immediately, not after the incomplete result has already been logged as complete. The distinction between the two categories cannot be left to the discretion of whoever happens to be managing the case at that moment.

A hub program that cannot tell a pharmaceutical partner what percentage of its benefit verifications were completed electronically versus requiring manual intervention, and what the accuracy rate was across both categories, is not providing access intelligence. It provides activity logs. Those are not the same thing, and the difference shows where it matters most: whether patients start therapy, and how fast.

The technology to improve benefit verification at scale exists. What is not yet fully in place is the payer-side infrastructure that would make that technology complete by default for every specialty case. Until that gap closes, the programs that serve patients most reliably will be the ones built to work within the current reality, not the ones marketed around the future it promises.

If you’re looking for the speed of eBV and the accuracy of human-verified work, we should chat. Contact us here.